AI Analysis

How does SANN.SW make money? Does SANN.SW have pricing power? What's the Earnings Whisper? Will SANN.SW profit more as the business scales? What is SANN.SW's management track record? Is SANN.SW's current price justified?

Santhera Pharmaceuticals Holding AG

CHF 15.58 +$3.44 (+28.34%)

SIX · 15 Sep 2026 15:30 UTC

Previous Close

CHF 15.56

Day Range

CHF 15.3CHF 15.92

Year Range

CHF 9.38CHF 18.84

Market Cap

231.07M

AVG Volume

72.43K

Trailing/Forward PE

-4.08/91.65

PEG ratio

0.04

Dividend Yield

Next Earnings Date

2026-09-21

Primary Exchange

Swiss Exchange

PE Ratio

SANN.SW PE Ratio by year
Period	PE Ratio
Sep 25	9.66
Sep 25	12.64
Sep 25	13.15
Sep 25	12.67
Aug 25	12.28
Aug 25	12.89
Aug 25	12.17
Aug 25	11.66
Jul 25	13.26
Jul 25	12.64
Jul 25	12.46
Jul 25	10.86
Jul 25	10.71
Jun 25	10.66
Jun 25	10.5
Jun 25	10.86
Jun 25	12.33
May 25	11.6
May 25	10.98
May 25	11.44
May 25	11.73
May 25	13.06
Apr 25	13.21
Apr 25	12.64
Apr 25	11.41
Apr 25	11.44
Sep 11	1.5
Sep 11	1.64
Sep 11	1.78
Sep 11	1.75
Aug 11	1.75
Aug 11	1.75
Aug 11	1.46
Aug 11	1.48
Jul 11	1.86
Jul 11	1.87
Jul 11	2.17
Jul 11	2.25
Jul 11	2.18
Jun 11	2.24
Jun 11	2.24
Jun 11	2.12
Jun 11	2.12
May 11	2.12
May 11	2.12
May 11	2
May 11	1.79
Apr 11	1.72
Apr 11	1.71
Apr 11	1.77
Apr 11	1.78
Apr 11	1.84

Free Cash Flow Yield

SANN.SW Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-33.82%
Sep 26	-33.4%
Sep 26	-33.57%
Aug 26	-34.13%
Aug 26	-31.63%
Aug 26	-33.18%
Aug 26	-33.23%
Jul 26	-37.17%
Jul 26	-35.32%
Jul 26	-34.13%
Jul 26	-34.58%
Jul 26	-35.56%
Jun 26	-33.27%
Jun 26	-33.02%
Jun 26	-33.74%
Jun 26	-30.89%
May 26	-32.29%
May 26	-33.65%
May 26	-30.6%
May 26	-30.74%
Apr 26	-30.96%
Apr 26	-31.07%
Apr 26	-29.87%
Apr 26	-31.63%
Apr 26	-32.69%
Mar 26	3.23%
Mar 26	3.47%
Mar 26	3.17%
Mar 26	3.2%
Feb 26	2.9%
Feb 26	3.06%
Feb 26	3.01%
Feb 26	3.73%
Jan 26	3.88%
Jan 26	3.54%
Jan 26	3.92%
Jan 26	3.33%
Dec 25	3.89%
Dec 25	3.8%
Dec 25	3.97%
Dec 25	4.02%
Dec 25	4.02%
Nov 25	4.02%
Nov 25	4.04%
Nov 25	4.62%
Nov 25	4.8%
Oct 25	4.8%
Oct 25	4.85%
Oct 25	4.71%
Oct 25	4.73%
Oct 25	4.54%
Sep 25	9.29%
Sep 25	7.11%
Sep 25	6.83%
Sep 25	7.09%
Aug 25	7.31%
Aug 25	6.97%
Aug 25	7.38%
Aug 25	7.7%
Jul 25	6.77%
Jul 25	7.11%
Jul 25	7.21%
Jul 25	8.27%
Jul 25	8.38%
Jun 25	8.42%
Jun 25	8.55%
Jun 25	8.27%
Jun 25	7.28%
May 25	7.74%
May 25	8.18%
May 25	7.85%
May 25	7.66%
May 25	6.88%
Apr 25	6.8%
Apr 25	7.11%
Apr 25	7.87%
Apr 25	7.85%
Mar 25	5.91%
Mar 25	5.89%
Mar 25	5.87%
Mar 25	5.84%
Feb 25	5.42%
Feb 25	5.48%
Feb 25	5.37%
Feb 25	5.33%
Jan 25	5.14%
Jan 25	5.8%
Jan 25	6.29%
Jan 25	6.44%
Jan 25	6.09%
Dec 24	6.93%
Dec 24	8.42%
Dec 24	9.52%
Dec 24	10.95%
Nov 24	10.74%
Nov 24	11.01%
Nov 24	10.61%
Nov 24	10.18%
Nov 24	10.04%
Oct 24	9.69%

Price to Sales

SANN.SW Price to Sales by year
Period	Price to Sales
Sep 26	1.79
Sep 26	1.81
Sep 26	1.81
Aug 26	1.78
Aug 26	1.92
Aug 26	1.83
Aug 26	1.82
Jul 26	1.63
Jul 26	1.72
Jul 26	1.78
Jul 26	1.75
Jul 26	1.7
Jun 26	1.82
Jun 26	1.84
Jun 26	1.8
Jun 26	1.96
May 26	1.88
May 26	1.8
May 26	1.98
May 26	1.97
Apr 26	1.96
Apr 26	1.95
Apr 26	2.03
Apr 26	1.92
Apr 26	1.85
Mar 26	1.19
Mar 26	1.11
Mar 26	1.21
Mar 26	1.2
Feb 26	1.33
Feb 26	1.26
Feb 26	1.28
Feb 26	1.03
Jan 26	0.99
Jan 26	1.09
Jan 26	0.98
Jan 26	1.16
Dec 25	0.99
Dec 25	1.01
Dec 25	0.97
Dec 25	0.96
Dec 25	0.96
Nov 25	0.96
Nov 25	0.95
Nov 25	0.83
Nov 25	0.8
Oct 25	0.8
Oct 25	0.79
Oct 25	0.82
Oct 25	0.81
Oct 25	0.85
Sep 25	0.87
Sep 25	1.14
Sep 25	1.18
Sep 25	1.14
Aug 25	1.1
Aug 25	1.16
Aug 25	1.09
Aug 25	1.05
Jul 25	1.19
Jul 25	1.14
Jul 25	1.12
Jul 25	0.98
Jul 25	0.96
Jun 25	0.96
Jun 25	0.94
Jun 25	0.98
Jun 25	1.11
May 25	1.04
May 25	0.99
May 25	1.03
May 25	1.05
May 25	1.17
Apr 25	1.19
Apr 25	1.14
Apr 25	1.03
Apr 25	1.03
Mar 25	1.42
Mar 25	1.43
Mar 25	1.43
Mar 25	1.44
Feb 25	1.55
Feb 25	1.54
Feb 25	1.57
Feb 25	1.58
Jan 25	1.63
Jan 25	1.45
Jan 25	1.34
Jan 25	1.31
Jan 25	1.38
Dec 24	1.21
Dec 24	1
Dec 24	0.88
Dec 24	0.77
Nov 24	0.78
Nov 24	0.76
Nov 24	0.79
Nov 24	0.83
Nov 24	0.84
Oct 24	0.87

EV/EBITDA

SANN.SW EV/EBITDA by year
Period	EV/EBITDA
Mar 26	5.57
Mar 26	5.27
Mar 26	5.64
Mar 26	5.6
Feb 26	6.05
Feb 26	5.8
Feb 26	5.88
Feb 26	4.99
Jan 26	4.85
Jan 26	5.19
Jan 26	4.81
Jan 26	5.43
Dec 25	4.84
Dec 25	4.92
Dec 25	4.76
Dec 25	4.72
Dec 25	4.72
Nov 25	4.72
Nov 25	4.71
Nov 25	4.27
Nov 25	4.16
Oct 25	4.16
Oct 25	4.13
Oct 25	4.22
Oct 25	4.2
Oct 25	4.33
Sep 25	1.97
Sep 25	2.58
Sep 25	2.69
Sep 25	2.59
Aug 25	2.51
Aug 25	2.63
Aug 25	2.49
Aug 25	2.38
Jul 25	2.71
Jul 25	2.58
Jul 25	2.54
Jul 25	2.22
Jul 25	2.19
Jun 25	2.18
Jun 25	2.15
Jun 25	2.22
Jun 25	2.52
May 25	2.37
May 25	2.24
May 25	2.34
May 25	2.4
May 25	2.67
Apr 25	2.7
Apr 25	2.58
Apr 25	2.33
Apr 25	2.34
Mar 25	4.91
Mar 25	4.93
Mar 25	4.94
Mar 25	4.97
Feb 25	5.34
Feb 25	5.28
Feb 25	5.38
Feb 25	5.42
Jan 25	5.6
Jan 25	5
Jan 25	4.63
Jan 25	4.53
Jan 25	4.78
Dec 24	4.23
Dec 24	3.53
Dec 24	3.15
Dec 24	2.78
Nov 24	2.83
Nov 24	2.76
Nov 24	2.86
Nov 24	2.97
Nov 24	3
Oct 24	3.1
Oct 24	3.13
Oct 24	3.12
Oct 24	3.09
Sep 24	2.82
Sep 24	2.95
Sep 24	2.92
Sep 24	2.95
Aug 24	2.87
Aug 24	2.87
Aug 24	2.8
Aug 24	2.9
Aug 24	2.82
Jul 24	2.95
Jul 24	2.99
Jul 24	2.66
Jul 24	2.63
Jun 24	2.64
Jun 24	3.05
Jun 24	3.11
Jun 24	3.08
May 24	3.17
May 24	3
May 24	2.96
May 24	2.93
May 24	2.98

Price/Operating Cashflow

SANN.SW Price/Operating Cashflow by year
Period	Price/Operating Cashflow
Mar 26	29.83
Mar 26	27.75
Mar 26	30.34
Mar 26	30.07
Feb 26	33.21
Feb 26	31.44
Feb 26	32.03
Feb 26	25.82
Jan 26	24.84
Jan 26	27.2
Jan 26	24.56
Jan 26	28.89
Dec 25	24.76
Dec 25	25.31
Dec 25	24.25
Dec 25	23.97
Dec 25	23.97
Nov 25	23.97
Nov 25	23.86
Nov 25	20.83
Nov 25	20.04
Oct 25	20.04
Oct 25	19.85
Oct 25	20.44
Oct 25	20.36
Oct 25	21.22
Sep 25	10.54
Sep 25	13.78
Sep 25	14.34
Sep 25	13.82
Aug 25	13.39
Aug 25	14.05
Aug 25	13.28
Aug 25	12.71
Jul 25	14.46
Jul 25	13.78
Jul 25	13.59
Jul 25	11.84
Jul 25	11.68
Jun 25	11.63
Jun 25	11.45
Jun 25	11.84
Jun 25	13.45
May 25	12.66
May 25	11.98
May 25	12.48
May 25	12.79
May 25	14.25
Apr 25	14.4
Apr 25	13.78
Apr 25	12.44
Apr 25	12.48
Mar 25	11.98
Mar 25	12.03
Mar 25	12.06
Mar 25	12.12
Feb 25	13.07
Feb 25	12.93
Feb 25	13.18
Feb 25	13.28
Jan 25	13.76
Jan 25	12.2
Jan 25	11.25
Jan 25	11
Jan 25	11.62
Dec 24	10.21
Dec 24	8.41
Dec 24	7.44
Dec 24	6.46
Nov 24	6.59
Nov 24	6.43
Nov 24	6.67
Nov 24	6.95
Nov 24	7.05
Oct 24	7.31
Oct 24	7.39
Oct 24	7.36
Oct 24	7.27
Sep 24	5.66
Sep 24	5.9
Sep 24	5.85
Sep 24	5.9
Aug 24	5.76
Aug 24	5.76
Aug 24	5.63
Aug 24	5.81
Aug 24	5.66
Jul 24	5.91
Jul 24	5.98
Jul 24	5.37
Jul 24	5.31
Jun 24	5.32
Jun 24	6.08
Jun 24	6.21
Jun 24	6.15
May 24	6.32
May 24	5.99
May 24	5.92
May 24	5.87
May 24	5.96

Price to Book

SANN.SW Price to Book by year
Period	Price to Book
Sep 25	4.47
Sep 25	5.84
Sep 25	6.08
Sep 25	5.86
Aug 25	5.68
Aug 25	5.96
Aug 25	5.63
Aug 25	5.39
Jul 25	6.13
Jul 25	5.84
Jul 25	5.76
Jul 25	5.02
Jul 25	4.95
Jun 25	4.93
Jun 25	4.86
Jun 25	5.02
Jun 25	5.7
May 25	5.37
May 25	5.08
May 25	5.29
May 25	5.42
May 25	6.04
Apr 25	6.11
Apr 25	5.84
Apr 25	5.28
Apr 25	5.29
Mar 25	3.51
Mar 25	3.53
Mar 25	3.54
Mar 25	3.56
Feb 25	3.84
Feb 25	3.79
Feb 25	3.87
Feb 25	3.9
Jan 25	4.04
Jan 25	3.58
Jan 25	3.3
Jan 25	3.23
Jan 25	3.41
Dec 24	3
Dec 24	2.47
Dec 24	2.18
Dec 24	1.9
Nov 24	1.93
Nov 24	1.89
Nov 24	1.96
Nov 24	2.04
Nov 24	2.07
Oct 24	2.14
Oct 24	2.17
Oct 24	2.16
Oct 24	2.13
Sep 24	1.65
Sep 24	1.72
Sep 24	1.7
Sep 24	1.72
Aug 24	1.68
Aug 24	1.68
Aug 24	1.64
Aug 24	1.69
Aug 24	1.65
Jul 24	1.72
Jul 24	1.74
Jul 24	1.56
Jul 24	1.54
Jun 24	1.55
Jun 24	1.77
Jun 24	1.81
Jun 24	1.79
May 24	1.84
May 24	1.74
May 24	1.72
May 24	1.71
May 24	1.73
Apr 24	1.77
Apr 24	1.7
Apr 24	1.72
Apr 24	1.77
Sep 22	30.99
Sep 22	31.33
Sep 22	31.37
Sep 22	30.99
Aug 22	25.2
Aug 22	27.37
Aug 22	29.87
Aug 22	31.93
Jul 22	30.99
Jul 22	31.7
Jul 22	32.97
Jul 22	33.61
Jul 22	31.44
Jun 22	37.34
Jun 22	38.83
Jun 22	39.58
Jun 22	43.17
May 22	49.66
May 22	49.66
May 22	47.42
May 22	50.63
Apr 22	47.8

No video analysis for this stock yet. Request one from our team.

News: SANN.SW

globenewswire.com · 1 Jul 2026

Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®

Data support AGAMREE's potential use as a treatment across a broad range of chronic inflammatory rare diseases Pratteln, Switzerland, July 1, 2026 - Santhera Pharmaceuticals (SIX: SANN) today notes topline results from a two-part Phase 1 clinical study of AGAMREE conducted by its North American licensing partner, Catalyst Pharmaceuticals, Inc.

globenewswire.com · 1 Jul 2026

Santhera gibt Topline-Ergebnisse der klinischen Phase-1-Studie von Catalyst Pharmaceuticals zu AGAMREE® bekannt

Die Daten untermauern das Potenzial von AGAMREE als Therapie für ein breites Spektrum chronisch-entzündlicher seltener Erkrankungen Pratteln, Schweiz, 1. Juli 2026 - Santhera Pharmaceuticals (SIX: SANN) gibt heute die Topline-Ergebnisse einer zweiteiligen klinischen Phase-1-Studie zu AGAMREE bekannt, die von seinem nordamerikanischen Lizenzpartner Catalyst Pharmaceuticals, Inc.

AI Analysis

Santhera Pharmaceuticals Holding AG

Video analysis: SANN.SW

News: SANN.SW

Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®

Santhera gibt Topline-Ergebnisse der klinischen Phase-1-Studie von Catalyst Pharmaceuticals zu AGAMREE® bekannt

Similar companies